Close Menu

NEW YORK (GenomeWeb) – Veracyte announced yesterday that its Afirma Thyroid FNA analysis test, which uses a set of gene expression signatures to differentiate benign thyroid nodules from cancerous ones, will become an Aetna in-network test beginning July 1.

Afirma employs a 142-gene signature to identify benign thyroid nodules in patients whose fine needle aspiration biopsies are deemed indeterminate following traditional cytopathology review and thus face a potentially unnecessary diagnostic surgery.

The test first received a positive coverage decision by Aetna in mid-2013.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.